Author
Li Cao
Bio: Li Cao is an academic researcher from Sichuan University. The author has contributed to research in topics: Sarcopenia & Geriatrics. The author has an hindex of 15, co-authored 25 publications receiving 1323 citations.
Topics: Sarcopenia, Geriatrics, Medicine, Population, Geriatric Depression Scale
Papers
More filters
The Heart Research Institute1, Saint Louis University2, Wake Forest University3, University of Maryland, Baltimore4, Heidelberg University5, University of Florida6, University of Milan7, University of Miami8, University of Erlangen-Nuremberg9, Université du Québec à Montréal10, University of Otago11, University of Adelaide12, Agostino Gemelli University Polyclinic13, United States Department of Veterans Affairs14, Tufts University15, Kyung Hee University16, Dalhousie University17, King's College London18, Sichuan University19, The Chinese University of Hong Kong20, University of Western Australia21, National Institutes of Health22, National University of Singapore23, Uppsala University24, University of São Paulo25, Memorial Hospital of South Bend26, Vrije Universiteit Brussel27, Maastricht University28, Universidad Pública de Navarra29, Centre Hospitalier Universitaire de Toulouse30
TL;DR: Evidence-based clinical practice guidelines for screening, diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research (ICSFR) are presented.
Abstract: Sarcopenia, defined as an age-associated loss of skeletal muscle function and muscle mass, occurs in approximately 6 - 22 % of older adults. This paper presents evidence-based clinical practice guidelines for screening, diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research (ICSFR). To develop the guidelines, we drew upon the best available evidence from two systematic reviews paired with consensus statements by international working groups on sarcopenia. Eight topics were selected for the recommendations: (i) defining sarcopenia; (ii) screening and diagnosis; (iii) physical activity prescription; (iv) protein supplementation; (v) vitamin D supplementation; (vi) anabolic hormone prescription; (vii) medications under development; and (viii) research. The ICSFR task force evaluated the evidence behind each topic including the quality of evidence, the benefitharm balance of treatment, patient preferences/values, and cost-effectiveness. Recommendations were graded as either strong or conditional (weak) as per the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Consensus was achieved via one face-to-face workshop and a modified Delphi process. We make a conditional recommendation for the use of an internationally accepted measurement tool for the diagnosis of sarcopenia including the EWGSOP and FNIH definitions, and advocate for rapid screening using gait speed or the SARC-F. To treat sarcopenia, we strongly recommend the prescription of resistance-based physical activity, and conditionally recommend protein supplementation/a protein-rich diet. No recommendation is given for Vitamin D supplementation or for anabolic hormone prescription. There is a lack of robust evidence to assess the strength of other treatment options.
466 citations
University of Queensland1, Changi General Hospital2, Tan Tock Seng Hospital3, National University of Singapore4, The Chinese University of Hong Kong5, Sichuan University6, University of the Philippines7, University of Malaya8, Kyung Hee University9, Taipei Veterans General Hospital10, Dalhousie University11, Centre Hospitalier Universitaire de Toulouse12, Capital Medical University13, Catholic University of the Sacred Heart14, Columbia University15, Saint Louis University16, University of Western Australia17
TL;DR: The recommendations provided herein are intended for use by healthcare providers in their management of older adults with frailty in the Asia Pacific region and it is proposed that regional guideline support committees be formed to help provide regular updates to these evidence-based guidelines.
363 citations
TL;DR: A number of consensus groups have provided similar definitions where sarcopenia is now defined as loss of function coupled with loss of muscle mass, and all of the definitions have been demonstrated to predict functional decline, hospitalization, and mortality in both community-dwelling older persons and residents in nursing homes.
263 citations
TL;DR: Sarcopenia is a predictor of all-cause mortality among community-dwelling older people and it is important to diagnose sarcopenia and to intervene, in order to reduce mortality rates in the elderly.
195 citations
TL;DR: The SARC-F scale can identify old Chinese people with impaired physical function who may suffered from sarcopenia and may be a simple and useful tool for screening individuals with impairment physical function.
Abstract: Introduction
The SARC-F scale is a newly developed tool to diagnose sarcopenia and obviate the need for measurement of muscle mass. SARC-F ≥ 4 is defined as sarcopenia. The questions of SARC-F cover physical functions targeting sarcopenia or initial presentation for sarcopenia. The aim of the study is to explore the application of SARC-F in the Chinese people.
108 citations
Cited by
More filters
National Yang-Ming University1, The Chinese University of Hong Kong2, Mahidol University3, University of Tokyo4, Seoul National University Bundang Hospital5, Peking Union Medical College Hospital6, Kyung Hee University7, Nagoya University8, Seoul National University9, Taipei Veterans General Hospital10, Ajou University11, Tan Tock Seng Hospital12, Osaka University13, University of Tsukuba14, Chinese Ministry of Health15
TL;DR: The Asian Working Group for Sarcopenia 2019 introduces "possible sarcopenia," defined by either low muscle strength or low physical performance only, specifically for use in primary health care or community-based health promotion, to enable earlier lifestyle interventions.
2,287 citations
TL;DR: The new ICD‐10‐CM (M62.84) code for sarc Openia represents a major step forward in recognizing sarcopenia as a disease and should lead to an increase in availability of diagnostic tools and the enthusiasm for pharmacological companies to develop drugs for sarc openia.
Abstract: The new ICD-10-CM (M62.84) code for sarcopenia represents a major step forward in recognizing sarcopenia as a disease. This should lead to an increase in availability of diagnostic tools and the enthusiasm for pharmacological companies to develop drugs for sarcopenia.
678 citations
TL;DR: In this article, the authors performed a systematic review to assess the short-, middle and long-term consequences of sarcopenia, and the results showed a higher rate of mortality among sarcopenic subjects (pooled OR of 3.596 (95% CI 2.96-4.37).
Abstract: Objective
The purpose of this study was to perform a systematic review to assess the short-, middle- and long-term consequences of sarcopenia.
Methods
Prospective studies assessing the consequences of sarcopenia were searched across different electronic databases (MEDLINE, EMBASE, EBM Reviews, Cochrane Database of Systematic Reviews, EBM Reviews ACP Journal Club, EBM Reviews DARE and AMED). Only studies that used the definition of the European Working Group on Sarcopenia in Older People to diagnose sarcopenia were included. Study selection and data extraction were performed by two independent reviewers. For outcomes reported by three or more studies, a meta-analysis was performed. The study results are expressed as odds ratios (OR) with 95% CI.
Results
Of the 772 references identified through the database search, 17 were included in this systematic review. The number of participants in the included studies ranged from 99 to 6658, and the duration of follow-up varied from 3 months to 9.8 years. Eleven out of 12 studies assessed the impact of sarcopenia on mortality. The results showed a higher rate of mortality among sarcopenic subjects (pooled OR of 3.596 (95% CI 2.96–4.37)). The effect was higher in people aged 79 years or older compared with younger subjects (p = 0.02). Sarcopenia is also associated with functional decline (pooled OR of 6 studies 3.03 (95% CI 1.80–5.12)), a higher rate of falls (2/2 studies found a significant association) and a higher incidence of hospitalizations (1/1 study). The impact of sarcopenia on the incidence of fractures and the length of hospital stay was less clear (only 1/2 studies showed an association for both outcomes).
Conclusion
Sarcopenia is associated with several harmful outcomes, making this geriatric syndrome a real public health burden.
600 citations
TL;DR: This work advocates change towards individually tailored interventions that preserve an individual's independence, physical function, and cognition by promoting the recognition of frailty, furthering advancements in evidence-based treatment options, and identifying cost-effective care delivery strategies.
567 citations